What Caught Our Attention in the Investment World? – Week of July 25-29, 2022

By Kuldip K. Ambastha

On Wednesday, July 27, 2022, the stock of global pharmaceutical company Teva Pharmaceutical Industries Limited (TEVA) rose in price by +28.4% per share. Teva is the world’s largest generic medicine producer, and has been struggling for the last five years because of weakness in the American generic medicine sector plus intense competition against its Copaxone multiple sclerosis drug offering. However, the stock on Wednesday benefited from the conclusion of many years of negotiation related to opioid lawsuits. A proposed $4.35 billion settlement for the relevant American lawsuits was received warmly, but still needs to be finalized and approved before taking effect. If the proposal ends up being successfully implemented in full, it will clear the way for Teva to have stronger revenue growth with less legal uncertainty in the future.

Keywords – Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Industries, Teva Pharmaceutical, Teva, TEVA, pharmaceutical, medicine, generic, multiple sclerosis, Copaxone, opioids, settlement, revenues, law.

Disclosure – The principals and clients of Ambastha Financial LLC have no positions in TEVA.

Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2022 – Ambastha Financial LLC.




Leave a Reply

Your email address will not be published. Required fields are marked *